What is Pulmonx Corporation's SG&A?

Pulmonx Corporation (LUNG) reported SG&A of $24.1M in Q1 2026.

How has Pulmonx Corporation's SG&A changed year-over-year?

Pulmonx Corporation's SG&A decreased by 7.8% year-over-year, from $26.15M to $24.1M.

What is the long-term trend for Pulmonx Corporation's SG&A?

Over 4 years (2021 to 2025), Pulmonx Corporation's SG&A has grown at a 9.7% compound annual growth rate (CAGR), from $69.87M to $101.31M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Pulmonx Corporation LUNG SG&A

SG&A at other companies

Intuitive SurgicalISRG

$613.3M+8.9%

Theravance BiopharmaTBPH

$17.72M-3.5%

LQD

Liquidia CorporationLQDA

$46.94M+56.1%

United TherapeuticsUTHR

$184.1M+8.2%

Viemed Healthcare, Inc.VMD

$34.79M+22.4%

Zevra Therapeutics, Inc.ZVRA

$20.78M+6.3%

Other financials

Income statement

See full

Revenue$20.6M-8.7%

Gross profit$16.0M-1.8%

Operating income-$13.0M+11.0%

Net income-$13.7M+5.5%

EPS (diluted)-$0.33+8.3%

Balance sheet

See full

Cash & equivalents$61.0M-2.4%

Total debt$56.3M-1.2%

Total equity$45.8M-41.1%

Total assets$120.0M-20.4%

Cash flow

See full

Operating cash flow-$10.1M+23.6%

CapEx$9.0K-97.0%

Free cash flow-$10.1M+25.3%

Valuation

See full

Market cap$54.91M-43.7%

Enterprise value$50.17M-39.2%

P/S0.6×-0.5×

Profitability

See full

Gross margin75.5%+2.0pp

Operating margin-58.8%-5.8pp

Net margin-60.1%-4.4pp

FCF margin-33.2%-4.4pp

Returns & leverage

See full

Return on equity-86.2%+62.6pp

Debt / equity1.2×+0.5×

Current ratio4.9×-0.1×

Where this comes from

Reported directly by Pulmonx Corporation in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Pulmonx Corporation’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pulmonx Corporation's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Pulmonx Corporation's SG&A?: Pulmonx Corporation (LUNG) reported SG&A of $24.1M in Q1 2026.
How has Pulmonx Corporation's SG&A changed year-over-year?: Pulmonx Corporation's SG&A decreased by 7.8% year-over-year, from $26.15M to $24.1M.
What is the long-term trend for Pulmonx Corporation's SG&A?: Over 4 years (2021 to 2025), Pulmonx Corporation's SG&A has grown at a 9.7% compound annual growth rate (CAGR), from $69.87M to $101.31M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.